Biological therapy in genital psoriasis in women

Burlando, Martina; Herzum, Astrid; Carmisciano, Luca; Cozzani, Emanuele; Parodi, Aurora

doi:10.1111/dth.13110

Cited by 11 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 In 25 women affected by GenPs, anti-IL17 (Secukinumab, Ixekizumab) and anti-IL12/23 (Ustekinumab) agents showed a higher clinical benefit than TNF alpha blockers. 9 A successful response of GenPs to ixekizumab was recently reported in six patients with moderate-to-severe psoriasis. 8 Our results showed that ixekizumab induced a rapid onset of clinical response, as demonstrated by a 51.4% mean reduction of s-PGA-G at week 4 followed by a consistent further improvement demonstrated by 91.4% mean reduction of s-PGA-G after 24 weeks of treatment.…”

Section: Discussionmentioning

confidence: 98%

“…Ixekizumab was superior to placebo at week 12, with 73.3% of patients achieving clear or almost clear genital skin. However, real‐life experiences on the treatment of GenPs with ixekizumab are limited to date 8,9 …”

Section: Introductionmentioning

confidence: 99%

“…However, real-life experiences on the treatment of GenPs with ixekizumab are limited to date. 8,9 We report our experience with ixekizumab in the treatment of GenPs in a case series of adult patients with moderate-to-severe plaque psoriasis over a period of 24 weeks. Site of genital involvement was recorded and classified as pubis, shaft, foreskin, glans, scrotum and perineum lesions for males and mons pubis, labia majora, labia minora, anterior commissure, interlabial groove and perineum lesions for females, in order to distinguish patients with GenPs from patients with inverse psoriasis.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24‐week real‐life experience

Calianno

Esposito

Fidanza

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Genital psoriasis (GenPs) has been traditionally considered a difficult to treat psoriasis area. Ixekizumab was the first biologic agent demonstrating efficacy and safety in a formal clinical trial on GenPs; however, real-life experiences are limited. To assess real-life effectiveness and safety of ixekizumab in the treatment of GenPs in a case series of patients with moderate-to-severe plaque psoriasis. Adult patients with moderate-to-severe plaque psoriasis involving the genital area received subcutaneous ixekizumab. Evaluation of disease severity, clinical symptoms, and quality of life was performed at baseline, after 4, 16, and 24 weeks of treatment. Assessment tools were: Static Physician's Global Assessment of Genitalia (sPGA-G), Psoriasis Area and Severity Index (PASI) score, Itch Numerical-Rating-Score (Itch-NRS), and Dermatology-Life-Quality-Index (DLQI). Adverse events were recorded. A total of 14 patients were treated with ixekizumab achieving consistent and significant reduction of disease and quality of life parameters, with a mean percentage reduction from baseline to week 24 of 91.4% for sPGA-G, 95.2% for PASI, 95.6% for Itch-NRS, and 93.7% for DLQI. Ixekizumab treatment was well tolerated. Ixekizumab significantly improved disease severity, itch, and quality of life with an acceptable safety profile in a real-life setting in adult patients affected by GenPs.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24‐week real‐life experience

Calianno

Esposito

Fidanza

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Недавнее сообщение M. Burlando с соавт. (2020) еще раз подтвердило, что лучший эффект у пациентов с псориазом половых органов, получавших ГИБП, был отмечен в группе пациентов, получавших секукинумаб и иксекизумаб [27]. Остальные ГИБП обеспечивали недостаточную эффективность.…”

Section: Discussionunclassified

Clinical evidence of therapy for genital psoriasis by biologic agents

Sokolovskiy

Кохан

2021

Vestnik dermatologii i venerologii

View full text Add to dashboard Cite

Data in the scientific literature on the use of biologic therapy in localized forms of psoriasis elucidate mostly the problems of treatment of palmoplantar, scalp psoriasis and nail psoriasis. At the same time, the number of scientific data on the effect of biological therapy on genital psoriasis is extremely limited. Important that the quality of life on patients with genital psoriasis has very low level, which indicates a significant influence on the psychological and social well-being. At the same time, the limited number of therapeutic approaches makes this problem even more urgent. Unfortunately, special clinical trials for such patients are rather an exception. Ixekizumab has been reported an effectiveness for patients with anogenital psoriasis. New data on the comparative efficacy of ixekizumab and secukinumab give hope us for new opportunity for the treatment of genital psoriasis.

show abstract

“…Several papers have demonstrated significant improvement in genital lesion appearance, itch, sexual health, and quality of life in resistant genital psoriasis treated with ixekizumab. [49][50][51][52] A randomized, placebo-controlled, phase III clinical trial demonstrated the longterm efficacy and safety of ixekizumab for up to 52 weeks [51]. Patients received either ixekizumab 80 mg (n = 75) or placebo (n = 74) every 2 weeks up to week 12, then entered an openlabel period where all patients received ixekizumab 80 mg every 4 weeks up to week 52.…”

Section: Il-17 Inhibitorsmentioning

confidence: 99%

Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management

Hong

Mosca

Hadeler

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Genital and inverse psoriasis can develop in more than one-third of patients who have psoriasis. Psoriatic plaques in the genital and intertriginous skin are challenging to treat because the skin is thin and often occluded, making it more sensitive to certain therapies. Traditional guidelines indicate topical therapies, such as corticosteroids, topical calcineurin inhibitors (TCI), and vitamin D analogs as firstline recommendation in treating genital and inverse psoriasis. There have been developments in the treatment of genital and inverse psoriasis using systemic therapies, including IL-17 inhibitors and PDE-4 inhibitors.

show abstract

Biological therapy in genital psoriasis in women

Abstract: Genital psoriasis (GenPs) is a frequent manifestation of psoriasis, causing distress, especially in women. We prospectively studied a population of 74 psoriatic women with severe and generalized psoriasis eligible to biologic therapy, to examine which biologic

Cited by 11 publications

References 8 publications

Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24‐week real‐life experience

Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24‐week real‐life experience

Clinical evidence of therapy for genital psoriasis by biologic agents

Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management

Contact Info

Product

Resources

About